NEW YORK (GenomeWeb News) – Bruker today announced it has licensed intellectual property from the Erasmus Medical Center for the rapid testing of beta-lactamase activity using MALDI-TOF technology.
The method being licensed is compatible with the Bruker MALDI Biotyper system, which uses MALDI-TOF mass spectrometry for identifying microorganisms, the company said.